13F Holdings
中文EN

ABOS Acumen Pharmaceuticals, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1576885 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY22.0%
TTM EPS YoY29.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-162.7%
ROA-91.3%
ROIC (approx.)-195.6%
Asset turnover—

Leverage & solvency

Liabilities / assets59.6%
Debt / equity0.76x
Current ratio1.89x
Interest coverage-24.65x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$104.89M$93.80M$42.32M$32.36M$12.30M
SG&A expense$18.95M$20.22M$18.82M$12.88M$7.28M
Operating income-$123.83M-$114.02M-$61.14M-$45.24M-$19.58M
Interest expense$4.22M$4.07M$581,000$0—
Income tax$0$0$0$0$0
Net income-$121.33M-$102.33M-$52.37M-$42.86M-$100.61M
EBITDA-$123.77M-$113.95M-$61.08M-$45.20M-$19.58M
EPS (basic)-2.00-1.71-1.08-1.06-5.02
EPS (diluted)-2.00-1.71-1.08-1.06-5.02
Weighted avg. shares (diluted)60.56M60.01M48.61M40.60M20.06M
Balance sheet
Cash & equivalents$53.99M$35.86M$67.12M$130.10M$122.16M
Short-term investments$62.88M$135.93M$176.64M$47.50M$72.08M
Current assets$122.25M$178.31M$246.62M$180.33M$198.66M
PP&E, net$103,000$73,000$122,000$165,000$36,000
Total assets$122.83M$238.99M$310.12M$196.59M$230.33M
Current liabilities$30.01M$27.61M$12.97M$7.81M$5.15M
Short-term debt$8.77M$0———
Long-term debt$22.40M$29.42M$29.90M$0—
Total debt$31.16M$29.42M$29.90M$0—
Total liabilities$52.40M$57.18M$43.15M$7.81M$5.15M
Shareholders' equity$70.43M$181.82M$266.97M$188.78M$225.18M
Net debt-$22.83M-$6.44M-$37.22M-$130.10M—
Shares outstanding60.58M60.09M57.91M41.03M40.47M
Cash flow statement
Operating cash flow-$115.54M-$86.22M-$43.06M-$35.15M-$17.96M
Capital expenditure$88,000$16,000$21,000$161,000$40,000
Free cash flow-$115.63M-$86.23M-$43.09M-$35.31M-$18.00M
Investing cash flow$133.93M$48.03M-$171.67M$39.19M-$104.12M
Financing cash flow-$34,000$6.93M$151.75M$3.91M$200.47M
Depreciation & amortization$58,000$63,000$61,000$32,000$4,000
Stock-based compensation$9.85M$9.63M$6.14M$3.06M$922,000

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.